The upregulation of CAMP in both COVID-19 and GBS patients was observed in our study, but it is not clear whether the positive immunomodulatory activity directly impacts disease outcomes or if the deregulation of expression leads to a negative effect. This evidence concerns the gene CAMP and Guillain-Barre syndrome.